Chinese biotech company BioCytogen has recently completed a series D+ round of financing of RMB970 million yuan.
This round of financing was led by CMB International, followed by SDIC Ventures, China Life Equity, Bencao Capital, Tongchuangweiye and Pax Capital.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription?